Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects

Oncologist

Volumn 5, Issue 5, 2000, Pages 388-392

  Muchmore, D B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cholesterol; Estrogen; Osteoporosis; Raloxifene; Selective estrogen receptor modulators; Tamoxifen; Uterus

Indexed keywords

ANTIESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESTROGEN ACTIVITY; FEMALE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 0033781929     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-5-388     Document Type: Conference Paper

References (26)

1. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
2. Biologic activity of tamoxifen at low doses in healthy women
3. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
4. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
5. Molecular basis of agonism and antagonism in the oestrogen receptor
6. Identification of an estrogen response element activated by 17beta-estradiol and raloxifene
7. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
8. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
9. Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene
10. Hypocholesterolemic activity of raloxifene (LY 139481): Pharmacological characterization as a selective estrogen receptor modulator
11. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
12. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
13. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer
14. Effects of raloxifene and hormone replacement therapy on homocysteine and C-reactive protein levels in postmenopausal women
15. Coronary heart disease mortality and adjuvant tamoxifen therapy
16. Selective estrogen receptor modulators: Pharmacological profile in the rat uterus
17. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial
18. Uterine effects of three-year raloxifene therapy in postmenopausal women younger than age 60
19. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium
20. Raloxifene: A selective estrogen receptor modulator
21. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
22. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
23. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study
24. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors
25. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group
26. The side effect profile in post menopausal women treated with raloxifene, HRT, estrogen (ERT) or placebo